Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study

Clin Invest Med. 1997 Oct;20(5):300-7.

Abstract

Objective: To compare the histopathologic features and expression of p53 and c-erb B2 in the tumours detected by mammography only (clinically occult tumours) and the tumours detected by a nurse examiner (clinically palpable tumours).

Setting: London branch of the Ontario Breast Screening Program, which uses both clinical breast examination and mammography as screening methods.

Interventions: Pathologic review and immunohistochemical staining of all tumours detected between 1990 and 1993.

Outcome measures: Categorization of tumours by detection method and analysis of tumour size, grade, type, lymph node status and c-erb B2 and p53 expression in each group.

Results: From 1990 to 1993, 131 tumours were detected in patients ranging in age from 50 to 85 years (median 63 years). Sixty-seven occult tumours and 64 palpable lesions were detected. The occult tumours were significantly smaller (1.34 cm v. 2.29 cm, p < 0.0001) than the palpable ones and included a higher proportion of special-type lesions and ductal carcinoma in situ (43.3% v. 10.9%, p < 0.0001). Occult invasive carcinomas were of lower grade than palpable carcinomas (68.4% grade 1, 21.1% grade 2, 10.5% grade 3 v. 32.8% grade 1, 36.1% grade 2, 31.1% grade 3, p < 0.0001). Fewer occult lesions showed axillary nodal metastases (19.6% v. 40.6%, p = 0.02). No statistically significant differences were found for p53 or c-erb B2 positivity between the 2 groups.

Conclusion: Tumours detected by different screening methods in a screening program have different pathologic characteristics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / pathology
  • Carcinoma / chemistry
  • Carcinoma / diagnosis
  • Carcinoma / pathology
  • Carcinoma in Situ / chemistry
  • Carcinoma in Situ / diagnosis
  • Carcinoma in Situ / pathology
  • Carcinoma, Ductal, Breast / chemistry
  • Carcinoma, Ductal, Breast / diagnosis
  • Carcinoma, Ductal, Breast / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Mammography*
  • Middle Aged
  • Palpation*
  • Pilot Projects
  • Receptor, ErbB-2 / analysis
  • Tumor Suppressor Protein p53 / analysis

Substances

  • Tumor Suppressor Protein p53
  • Receptor, ErbB-2